Acquiring Company
Impact BioMedical
Acquired Company
Zoar Ltd
Description
Impact BioMedical Inc. and Zoar Ltd. are planning a merger that will create a new company with extensive expertise in pharmaceuticals. Following the completion of the merger, Impact stockholders will receive shares of Zoar Ltd. The merger aims to enhance capabilities in manufacturing and clinical development for critical drugs.
Don't miss Impact BioMedical's next move
Get an email the moment Impact BioMedical makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
M&A Insights
Based on deal dataFrequently asked
Who acquired Zoar Ltd?
Zoar Ltd was acquired by Impact BioMedical, based in Texas. The deal was reported on September 11, 2026. Impact BioMedical Inc. is a biopharmaceutical developer that creates innovative treatments and solutions. The company is publicly traded on the New York Stock Exchange American. Impact BioMedical is publicly traded (IBO) and operates in Biotechnology.
When did Impact BioMedical acquire Zoar Ltd?
Impact BioMedical's acquisition of Zoar Ltd was reported on September 11, 2026. Impact BioMedical Inc. and Zoar Ltd. are planning a merger that will create a new company with extensive expertise in pharmaceuticals. Following the completion of the merger, Impact stockholders will receive shares of Zoar Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Zoar Ltd do?
Zoar Ltd. specializes in the production of pharmaceutical ingredients and intermediates. The company is poised to contribute expertise in human health and wellness markets. It has significant intellectual property in its field. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.